EUVIMEDEUVIMED entdecken
Open Access

Circulating CD22 +/ CD19 −/ CD24 − progenitors and CD22 +/ CD19 +/ CD24 − mature B cells: Diagnostic pitfalls for minimal residual disease detection in B‐lymphoblastic leukemia

Ting Zhou, Jeremiah Karrs, Truc Ho, Alyssa Doverte, James N Kochenderfer, Nirali N Shah, Constance M Yuan iD, Hao-Wei Wang iD

Cytometry Part B: Clinical Cytometry · 2023-07 · 104 (4) · 294-303

DOI: 10.1002/cyto.b.22104 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cytometry Part B: Clinical Cytometry, online erschienen am 26.11.2022. Verfasst von Ting Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, B-Cell. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Multiparametric flow cytometry (MFC) has become a powerful tool in minimal residual disease (MRD) detection in B‐lymphoblastic leukemia/lymphoma (B‐ALL). In the setting of targeted immunotherapy, B‐ALL MRD detection often relies on alterative gating strategies, such as the utilization of CD22 and CD24. It is important to depict the full diversity of normal cell populations included in the alternative B‐cell gating methods to avoid false‐positive results. We describe two CD22‐positive non‐neoplastic cell populations in the peripheral blood (PB), including one progenitor population of uncertain lineage and one mature B‐cell population, which are immunophenotypic mimics of B‐ALL.

Methods

Using MFC, we investigated the prevalence and phenotypic profiles of both CD22‐positive populations in 278 blood samples from 52 patients with B‐ALL; these were obtained pre‐ and post‐treatment with CD19 and/or CD22 CAR‐T therapies. We further assessed whether these two populations in the blood were exclusively associated with B‐ALL or recent anticancer therapies, by performing the same analysis on patients diagnosed with other hematological malignancies but in long‐term MRD remission.

Results

The progenitor population and mature B‐cell population were detected at low levels in PB of 61.5% and 44.2% of B‐ALL patients, respectively. Both cell types showed distinctive and highly consistent antigen expression patterns that are reliably distinguishable from B‐ALL. Furthermore, their presence is not restricted solely to B‐ALL or recent therapy.

Conclusions

Our findings aid in building a complete immunophenotypic profile of normal cell populations in PB, thereby preventing misdiagnosis of B‐ALL MRD and inappropriate management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor B-Cell Lymphoblastic Leukemia-LymphomaLeukemia, B-CellHumansNeoplasm, ResidualFlow CytometryAntigens, CD19B-LymphocytesSialic Acid Binding Ig-like Lectin 2CD24 Antigen

Stichwörter der Autor:innen

B-lymphoblastic leukemiasimmunophenotypic mimicsminimal residual diseasemultiparametric flow cytometry

Substanzen

Antigens, CD19CD22 protein, humanSialic Acid Binding Ig-like Lectin 2CD24 protein, humanCD24 Antigen

Autor:innen und Institutionen

  • Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

ORCID-Profile: Constance M Yuan, Hao-Wei Wang

Förderung

  • Intramural NIH HHS

Zitieren

APA

Zhou, T., Karrs, J., Ho, T., Doverte, A., Kochenderfer, J. N., Shah, N. N., Yuan, C. M., & Wang, H. W. (2023). Circulating CD22 +/ CD19 −/ CD24 − progenitors and CD22 +/ CD19 +/ CD24 − mature B cells: Diagnostic pitfalls for minimal residual disease detection in B‐lymphoblastic leukemia. Cytometry Part B: Clinical Cytometry, 104(4), 294-303. https://doi.org/10.1002/cyto.b.22104

Vancouver

Zhou T, Karrs J, Ho T, Doverte A, Kochenderfer JN, Shah NN, et al. Circulating CD22 +/ CD19 −/ CD24 − progenitors and CD22 +/ CD19 +/ CD24 − mature B cells: Diagnostic pitfalls for minimal residual disease detection in B‐lymphoblastic leukemia. Cytometry Part B: Clinical Cytometry. 2023;104(4):294-303. doi:10.1002/cyto.b.22104

BibTeX
@article{Zhou2023,
  author = {Zhou, Ting and Karrs, Jeremiah and Ho, Truc and Doverte, Alyssa and Kochenderfer, James N and Shah, Nirali N and Yuan, Constance M and Wang, Hao-Wei},
  title = {Circulating CD22 +/ CD19 −/ CD24 − progenitors and CD22 +/ CD19 +/ CD24 − mature B cells: Diagnostic pitfalls for minimal residual disease detection in B‐lymphoblastic leukemia},
  journal = {Cytometry Part B: Clinical Cytometry},
  year = {2023},
  volume = {104},
  number = {4},
  pages = {294--303},
  doi = {10.1002/cyto.b.22104}
}
Kostenlos starten →